STANLEY SCHINKE, M.D.
Specialist · HEMET, CA
Individual Active NPI 1649277088
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 853 | 282,219 | $17,006,402 | $6,677,361 | $5,306,727 |
| 2023 | 967 | 314,696 | $7,931,684 | $6,037,555 | $4,795,084 |
| 2022 | 960 | 308,789 | $8,637,153 | $6,484,995 | $5,148,272 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | 43,500 | $1 | $1 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 23,400 | $48 | $38 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 17,301 | $8 | $6 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 16,302 | $0 | $0 |
| J0185 | Injection, aprepitant, 1 mg | 12,740 | $2 | $1 |
| J0897 | Injection, denosumab, 1 mg | 11,100 | $25 | $20 |
| J9299 | Injection, nivolumab, 1 mg | 11,000 | $31 | $25 |
| J9271 | Injection, pembrolizumab, 1 mg | 10,200 | $56 | $45 |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 8,700 | $6 | $4 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 7,540 | $47 | $37 |
| J9041 | Injection, bortezomib, 0.1 mg | 6,324 | $2 | $1 |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 3,020 | $40 | $32 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Specialist | 174400000X | ✓ | G55989 | CA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Specialist providers in California
- NPI 1245396191
- NPI 1235224049
- NPI 1184820987
- NPI 1811193618
- NPI 1730385535
- NPI 1447455423
- NPI 1154516664
- NPI 1750650982
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.